Shots:
- The P-llb/lll HERALD trial evaluating the safety & efficacy of CVnCoV in 40,000 with COVID-19 across 10 countries in Latin America & EU which conducted with Bayer, at least 13 variants circulating within the study population
- Results: vaccine efficacy (47%) & had failed to meet prespecified success criteria, a favorable safety profile was confirmed by DSMB. The analysis includes 134 cases in at least 2 wks. after 2nd dose was administered showed 57% of cases from variants of concern & only one was identified to original SARS-CoV-2 virus
- The results have been delivered to EMA & study will continue to final analysis & totality of data while initial analyses show age & variant dependent efficacy
Click here to read full press release/ article | Ref: CureVac | Image: DW
The post CureVac Report Results of CVnCoV in Second Interim Analysis of P-llb/lll HERALD Trial to Treat COVID-19 first appeared on PharmaShots.
